Live Breaking News & Updates on Information Center Prevention

Stay updated with breaking news from Information center prevention. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Kasus Covid-19 di Asean Tinggi, Menlu Retno Klaim Indonesia Sudah Membaik

Kasus Covid-19 di Asean Tinggi, Menlu Retno Klaim Indonesia Sudah Membaik
bisnis.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bisnis.com Daily Mail and Mail on Sunday newspapers.

United States , Jakarta Raya , Ministry Health English , Information Center Prevention , Secretary Claim Indonesia Already Improved , Jakarta Secretary Of State Marsudi , Region Southeast Asia , Director General , Read Also , Southeast Asia , Few Region , North America , News Good , Will Be Receive Million Vaccine , Control Disease , Option Under , ஒன்றுபட்டது மாநிலங்களில் , ஜகார்த்தா ராய , அமைச்சகம் ஆரோக்கியம் ஆங்கிலம் , தகவல் மையம் ப்ரெவெந்ஶந் , செயலாளர் உரிமைகோரல் இந்தோனேசியா ஏற்கனவே மேம்படுத்தப்பட்டது , பகுதி தென்கிழக்கு ஆசியா , இயக்குனர் ஜநரல் , ரெட் மேலும் , தென்கிழக்கு ஆசியா , சில பகுதி ,

Transgene Expands Phase II Clinical Trial of Therapeutic Vaccine TG4001 in Combination With Avelumab Versus Avelumab Monotherapy in Patients With HPV16-positive Anogenital Cancers

Transgene Expands Phase II Clinical Trial of Therapeutic Vaccine TG4001 in Combination With Avelumab Versus Avelumab Monotherapy in Patients With HPV16-positive Anogenital Cancers
-
Trial will focus on patients without liver metastases, based on encouraging data in Phase Ib/II study
-
Trial targets indications where clinical outcomes can be improved versus standard therapeutic options and immune checkpoint inhibitors ( ICIs )
-
Continued clinical collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer to conduct the expanded Phase II study
Regulatory News:
Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announces the expansion of a randomized, controlled study with TG4001 in combination with avelumab versus avelumab monotherapy in patients with HPV16-positive anogenital tumors (NCT: 03260023) ....

Distrito Federal , United States , United Kingdom , Lucie Larguier , Christophe Le Tourneau , Le Tourneau , Transgene Euronext , Sylvie Berrebi , Maud Brandely , Citigate Dewe Rogerson , Head Of The Department Drug Development , Information Center Statistics , Curie Institute , Merck Kga , Pfizer Inc , Merck Kgaa , Corporate Communications , Information Center Prevention , American Cancer Society , Euronext Paris , Drug Development , Principal Investigator , Chief Medical Officer , Positive Cancers , Artificial Intelligence , Approved Indications ,